Background/Aims: Colorectal cancer (CRC) is one of the leading causes of cancer-related death worldwide. Levistolide A (LA), a natural compound isolated from the traditional Chinese herb Ligusticum chuanxiong Hort, is used for treating cancer. In this study, we investigated the anticancer effect of LA in HCT116 and its isogenic p53-/-colon cancer cells, as well as the underlying mechanisms. Methods: MTT assay was used to evaluate the effect of LA on the viability of cancer cells. Apoptosis and reactive oxygen species (ROS) production by the cells were determined by flow cytometry. Protein expression was detected by western blotting.
Introduction
Colorectal cancer (CRC) is the second most commonly diagnosed cancer in women and third in men worldwide, with an incidence of 1.4 million new cases and 693,900 of death in 2012 according to the statistics from GLOBOCAN published in 2015 [1] . The major therapeutic regimen includes the combination of surgical procedure and chemotherapy. In the 1990s, targeted therapy was the main direction for development of anti-cancer therapies, and traditional drug screening from natural compounds was left behind. However, targeted therapy was soon found to be effective only for the short term, and therapy resistance was obvious. Currently, drug resistance and severe side effects impede the chemotherapy-based treatment strategies for cancer. Thus, there is a need to search for new therapeutic agents with fewer side effects, which target molecular signaling pathways in cancers including CRC. Therefore, in the past decade, natural compounds and their derivatives have come back to the spotlight and have redrawn public attention.
Natural products play a significant role in drug discovery and development, which includes but is not limited to the therapeutic development of anti-cancer drugs. A typical example of therapeutic development using natural product is the use of artemisinin in treating malaria, which has won the Nobel Prize. Notably, natural products and their derivatives are also important for the discovery and development of anticancer drugs due to their unique advantages of low cytotoxicity. Moreover, these products can reverse multidrug resistance of some chemotherapeutic compounds when used in combination [2] [3] [4] . According to a statistics published in 2016, from 1940 through the end of 2014, 49% of 175 small molecular compounds approved by the US FDA against cancer were natural products or direct derivatives of natural products [5] .
The traditional Chinese herb Ligusticum chuanxiong Hort, alone or in combination with other herbs as formula, has long been used for cancer treatment. Moreover, the active components of chuanxiong including sodium ferlate and chuanxiong polysaccharide have shown potential anticancer effects in various cancer cell line models, including the liver cancer cell line HepG2 and human colon cancer cell lines Moser and LoVo. LA is a compound isolated from chuanxiong, polymerized by two molecular ligustilide [6] . Recently, LA has been shown to synergize with vinorelbine in the induction of cancer cell cycle arrest at G2/M phase and apoptosis in breast cancer cells, as well as reverse P-glycoprotein-mediated multidrug resistance in human breast carcinoma cells [7] .
In the present study, we aimed to investigate the anti-cancer effects of LA and the underlying molecular mechanism using HCT116 colon cancer cells as an experimental model.
Materials and Methods

Chemicals and Reagents
Levistolide A (LA, Z, Z, 6, 7-cis, 6. 6, 7. 3a-di (3-butylidene-4,5-dihydrophthalide; Fig. 1A) ), a single compound isolated from the traditional Chinese herb Ligusticum chuanxiong Hort, was purchased from PureOne biotechnology (Shanghai, China). A 100 mM stock solution of LA was prepared by dissolving the compound in dimethyl sulfoxide (DMSO) and was kept frozen at -20°C until use. N-acetylcysteine (NAC) and methyl thiazolyl tetrazolium (MTT) were obtained from Sigma-Aldrich (St. Louis, MO). The cell cycle and apoptosis analysis kit (cat no: C1052) and DCFH-DA (cat no: S0033) were obtained from Beyotime Biotech (Nantong, China). Antibodies against phospho-PERK, BIP, CHOP, eIF2 , cleaved PARP and GAPDH were purchased from Cell Signaling Technology (Beverly, USA).
Cell Culture and treatment HCT116 human colon cancer cells were obtained from Cell Resource Center of Chinese Academy of Medical Sciences; its isogenic p53 knockout (p53-/-) cells were kindly provided by Dr. Mian Wu (University of Science and Technology of China). The cells were maintained in DMEM supplemented with 10% heatinactivated FBS, 100 U/ml penicillin and 100 μg/ml streptomycin at 37°C in a humidified incubator with 5% CO 2 in air. For all experiments, cell cultures at 70-80% confluence were used. Treatment was performed by direct addition of different concentrations of LA stock solution into the culture media and incubation for 24 h or 48 h. Cells in the control group were treated with equal amount of DMSO.
Cell viability Assay
Approximately 7,000 cells were seeded in each well of 96-well plates. After 24 h of incubation, the cancer cells were incubated with the indicated concentrations of LA for another 24 h or 48 h. Then, 10 µl MTT reagent (5 mg/ml) was added to each well and incubated for 4 h at 37°C in an incubator after which the medium was removed and 150 µl DMSO was added. The culture plates were placed on a shaker for gentle shaking at room temperature for 10-15 min. The absorbance at 570 nm was recorded on a spectrophotometer.
Lactate dehydrogenase (LDH) release assay
Cell necrosis was evaluated by quantification of plasma membrane integrity monitored by LDH release into the medium. HCT116 cells were seeded in 96-well plates at the density of 7,000 cells per well and then incubated with different concentration of LA (0, 12.5, 25, 50 and 100 µM) for 24 h; DMSO was added to the control wells. LDH released into the supernatant of the culture medium was determined by LDH cytotoxicity detection assay kit (Beyotime, Jiangsu, China) according to the manufacturer's instructions. The necrosis rate was calculated using the equation: (experimental release-control release)/ (maximum release-control release) ×100.
Apoptosis assay
Cell apoptosis was determined by using an annexin V-FITC/PI staining kit (Beyotime Institute of Biotechnology, China) by FACS, following the manufacturer's instructions. Briefly, after treatment, the cells were rinsed twice with cold PBS and then resuspended in 1X binding buffer at a concentration of ~1 x 10 6 cells/ml. The cell suspension was incubated with 5 µl annexin V-FITC for 15 min and 10 μl PI for 5 min at room temperature in the dark and analyzed by flow cytometry within 1 h.
Caspase-3 activity assay
Caspase-3 activity in control and LA-treated HCT116 cells was determined using a caspase-3 activity kit (Beyotime Institute of Biotechnology, China) following the provided instructions. Briefly, cell culture medium was collected and combined with the cells digested by trypsin after 24 h treatment. After centrifugation, the cell pellets were subjected to lysis by lysis buffer and incubated on ice for 15 min. Lysates were centrifuged at 16,000 g at 4°C for 15 min. Caspase-3 activity was determined by its catalytic substrate peptides Ac-DEVD-pNA. Release of catalytic production p-nitroanilide was quantified by measuring absorbance value at the wavelength at 405 nm.
Quantification of reactive oxygen species (ROS)
Intracellular ROS production was detected by FACSCalibur flow cytometer using the peroxidesensitive fluorescent probe 2′,7′-dichlorofluorescin diacetate (DCFH-DA), according to the manufacturer's instructions. Briefly, after treatment, cells were incubated with 10 µM DCFH-DA diluted with serum-free culture medium for 20 min at 37°C, then washed three times with serum-free culture medium, re-suspended in ice-cold PBS and kept in dark. The intracellular peroxide levels, which represent the levels of ROS, were measured by an FACS Caliber flow cytometer that emission wavelength at 525 nm. 10,000 individual cells for each group were acquired using the CellQuest™ software (BD Biosciences, CA) and analyzed by the FlowJo 7.6 software (TreeStar, San Carlos, CA).
Western blot analysis
Cells were washed twice with cold PBS and lysed with ice-cold modified RIPA buffer (25 mM Tris·HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, and 5% glycerol) containing phosphatase and protease inhibitors cocktail (Thermo Fisher Scientific, Rockford, IL). Whole cell lysates were centrifuged for 25 min at 13,000 g at 4°C, supernatants were collected, and protein concentration was determined using BCA protein assay (Bio-Rad Laboratories, Hercules, CA). Proteins were separated on 10%-12% reducing SDS-PAGE and electroblotted onto Immobilon-P polyvinylidene fluoride membranes. Immunoblots were blocked with 5% non-fat dry milk in tris-buffered saline and 0.05% tween 20 (TBST) for 60 min at room temperature and incubated overnight at 4°C with the indicated primary antibodies. Blots were washed in TBST and incubated with Horseradish peroxidase-conjugated secondary antibodies (1:20,000, Pierce, Rockford, IL, USA) for 1 h at room temperature. Antigen-antibody complexes were visualized by chemiluminescence using ECL kit (Pierce Rockford, IL, USA). All primary antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA).
Results
LA suppresses the survival of HCT116 cell lines in a time-and dose-dependent manner
To determine the effects of LA on the growth of human colon cancer cells, HCT116 and its isogenic p53-/-cells were treated with different doses of LA for 24 h or 48 h, and MTT assay was performed to investigate cell viability. DMSO was used as vehicle control for LA. The clinical drug 5-fluorouracil (5-FU) was used as positive control. As shown in Fig. 1B , treatment with LA inhibited the viability of both HCT116 wild type and HCT116 p53-/-cells in a dose-and time-dependent manner.
LA induces apoptosis in cancer cells
We tested whether LA could cause necrosis of cancer cells by measuring LDH release by the cells 24 h after LA treatment (Fig. 1C) . The results showed that low levels of LDH release occurred upon LA treatment-approximately 6.95% and 8.33% when incubated with 50 and 100 µM LA, respectively. We further examined the pro-apoptotic effect of LA on cancer cells. HCT116 and its isogenic p53-/-cells were treated with different concentrations of LA for 24 h, and apoptosis was detected by annexin V-FITC/PI staining in combination with flow cytometry. As shown in Fig. 2A and B, a dose-dependent increase in the fraction of apoptotic cells was observed in HCT116 cells, and the proportions of annexin V-FITC and PI doubly stained cells were 7.1%, 10.9% and 27.3% in the control, low LA (50 µM) and high LA (100 µM) groups, respectively. In accordance with the MTT results, a reduced apoptotic rate (~15%) was observed in the p53-/-HCT116 cells compared with 27.3% in HCT116 cells after 24 h LA-treatment, which increased to approximately 42% in p53-/-HCT116 and 55% in HCT116 cells during 48 h LA-treatment (Fig. 2C) . To further confirm that LA can trigger apoptosis, we determined the activity of apoptosis executioner, caspase-3. The results showed that caspase-3 activity was significantly up-regulated by LA in the cancer cells (Fig. 2D) . Furthermore, we demonstrated that LA induced the cleavage of PARP, which is a substrate of caspase-3 (Fig. 2E) .
LA increases ROS production in cancer cells
Studies have suggested that ROS are an important modulator of the response to cancer therapeutic agents [8] . We therefore determined whether ROS generation is involved in the growth inhibition and pro-apoptotic effect elicited by LA. As shown in Fig. 3 , ROS production was increased by LA in a dose-dependent manner. Pretreatment of the cancer cells with 5 
LA induces ER stress in cancer cells
Recently, studies showed that ER stress can be activated as a downstream event of oxidative stress-mediated apoptosis, and in several instances, both of these processes can occur together [9] [10] [11] . To investigate the role of ER stress in LA-induced apoptosis, the expression of ER stress-related proteins, including Bip, p-eIF2α, and CHOP was measured by western blot analysis. The results showed that LA treatment significantly activated ER stress, as evidenced by the increase in the expression of ER stressrelated proteins (Fig. 4) . The expression of molecular chaperone Bip was increased by LA in a dose-dependent manner, and the phosphorylation of eIF2α was also increased by LA. Moreover, enhanced expression of the downstream response product of ER stress CHOP was observed.
ROS signal is upstream of ER stress in apoptosis induction by LA
To test whether ROS are a signal for apoptosis, we treated cells with the ROS scavenger NAC (5 mM) for 1 h prior to LA and quantified cell viability and apoptosis. The results showed that treatment with NAC, while preventing ROS generation (Fig. 3B ) was able to abrogate the inhibitory effect of LA on cell viability (Fig. 5D, E) and apoptosis (Fig. 5A, B) . More specifically, the proportion of apoptotic cells in the control cells, LA-treated cells and those treated with LA plus NAC was approximately 11.6%, 41.04%, and 22%, respectively.
In different studies, ROS have been shown to be upstream or downstream of ER stress [9, [12] [13] [14] [15] . To clarify whether ROS are upstream or downstream of ER stress in LA-induced apoptosis, we tested whether NAC could inhibit ER stress signals. The results showed that after blockage of ROS production by NAC, the LA-induced activation of ER stress was A previous study showed that the chloroform extracts from Angelicae sinensis, ligustilide, can reverse P-glycoprotein-mediated MDR in human breast carcinoma Bcap37/MDR1 cells and enhance the apoptotic effects of the chemotherapeutic drugs adriamycin and vincristine. The IC50 of LA was 89.31 and 93.14 μmol/L in Bcap37 and Bcap37/MDR1 cells, respectively [7] . In the present study, we demonstrated that LA can inhibit the viability of human colon cancer HCT116 cells in a time-and dose-dependent manner (Fig. 1B) and induce apoptosis of the cancer cells (Fig. 2) , indicating that LA can be a candidate anticancer agent against human colon cancer. Thus, it will be interesting to investigate the anti-cancer activity of LA in vivo in animal models. Moreover, since the tumor suppressor gene p53 plays a pivotal role in cancer development and mutations of the p53 gene occur in most CRCs, we further investigated LA-induced apoptosis in isogenic HCT116 p53-/-cells; the results showed that knockout of p53 decreased the sensitivity of the cells to drugs, which is consistent with our previous findings and those of many other studies [16, 17] .
Cancer cells are characterized by elevated level of ROS due to imbalanced redox homeostasis [18] . ROS play a controversial role in tumor progression and metastasis. Low to moderate levels of ROS may contribute to tumorigenesis, but excessive ROS production promotes cancer cell death [8] . Therefore, targeting ROS is an important anticancer therapeutic strategy. In fact, a large number of studies have demonstrated the induction of ROS-mediated apoptosis by various therapeutic drugs [19] [20] [21] . In this study, we found that LA triggered ROS generation (Fig. 3) and apoptosis (Fig. 2) , both of which were inhibited by the antioxidant NAC (Fig. 5A, B) , indicating that ROS are a signal that mediates LA-induced apoptosis. Normal ROS homeostasis is crucial for maintaining normal cell function. ROS are mainly produced in the mitochondria through metabolic reactions, in peroxisomes through β-oxidation of fatty acids and in the ER through protein oxidation [22] . Recently, ER stress inducers have drawn attention as potential anticancer drugs by inducing cancer cell death since ER stress can cause apoptosis in cancer cells [23] . Compelling evidence has demonstrated that both ROS generation and ER stress activation can be induced upon therapeutic treatment [24] . Evidence has shown that ER stress is a common response mechanism upon treatment with therapeutic agents. Thus far, dozens of drugs targeting the ER stress pathway have been approved by the FDA, including 5-fluorouracil, arsenic trioxide and bortezomib. ER stress disrupts cellular homeostasis by promoting the accumulation of misfolded or unfolded proteins within the ER lumen, leading to the activation of UPR aiming to restore ER homeostasis. The evolutionarily conserved UPR signaling pathway is regulated by three transmembrane proteins, namely, PERK, IRE1α and ATF-6 [25] . Among these, the PERK-mediated branch is the most commonly studied. ER stress is initiated with the sequestration of the ER resident chaperone Bip. Release of Bip results in the activation of PERK. Activated PERK phosphorylates eIF2α, which in turn activates the downstream transcription factors ATF4 and CHOP. CHOP is also known as a growth arrest and DNA damage gene 153, which acts as an executioner of the pro-apoptotic branch of ER stress [26, 27] . CHOP mediates cell death through various targeted transcriptional factors, including GADD34, Ero1L, Bim and DR5 [28] [29] [30] . Here, we explored the potential role of ER stress upon LA treatment in HCT116 cells. The results showed that LA activated the PERK/eIF2α/ CHOP axis, as evidenced by the enhanced protein expression of phosphorylated PERK and eIF2α as well as CHOP, which plays a convergent role in ER stress-mediated apoptosis and is activated by all three arms of ER stress sensors. Caspase-12 is localized to the ER and plays a central role in ER-stress-mediated apoptotic cell death [31] . However, it has also been reported that ER stress induces apoptosis in an apoptosome-dependent and caspase-12-independent mechanism in mice [32] . Our results showed that the activity of caspase-3 is up-regulated by LA (Fig. 2D) , whereas the activation of caspase-12 is not a significant event (data not shown), suggesting that LA induces apoptosis through the ER stress pathway that is independent of caspase-12.
Several groups have reported that ER stress increases ROS and antioxidants protect cells from ER stress-induced cell death [14, 15] . In our study, ROS generation was increased by LA in a dose-dependent manner, and blocking ROS production by NAC almost completely abrogated LA-induced apoptosis and dramatically attenuated LA-induced Bip, PERK and CHOP expression, indicating that ROS generation is an upstream event of ER stress induced by LA. The interplay between ROS and ER stress is controversial; ROS can either trigger the activation of ER stress or can be a consequence of ER stress [9, [12] [13] [14] [15] . We found that NAC was able to inhibit ROS production (Fig. 3B) , ER stress, cell viability and apoptosis (Fig.  5) triggered by LA, which suggests that ROS is upstream of ER stress in the induction of apoptosis by LA.
Overall, our results revealed for the first time that the natural compound LA triggered apoptotic cell death in HCT116 cells in the presence or absence of p53, which was accompanied by enhanced ROS production as well as ER stress activation. Blockage of ROS production using antioxidants such as NAC inhibited ER stress and apoptosis. Thus, our results suggested that LA induces apoptosis in colon cancer cells via ROS-mediated ER stress pathway.
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